Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients

Clinical Therapeutics

Volumn 23, Issue 8, 2001, Pages 1231-1244

  Smith, Patrick F ^a   Ballow, Charles H ^a   Booker, Brent M ^a   Forrest, Alan ^a   Schentag, Jerome J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Aztreonam; Pharmacodynamics; Pharmacokinetics; Tobramycin

Indexed keywords

AZTREONAM; TOBRAMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; DATA ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HOSPITAL PATIENT; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; SKIN INFECTION; TREATMENT OUTCOME;

EID: 0034870049     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80103-X     Document Type: Article

References (26)

1. Effect of dose and schedule on cefoperazone pharmacodynamics in an in vitro model of infection in a neutropenic host
2. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models
3. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins
4. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
5. Role of pharmacokinetics in the outcome of infections
6. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
7. Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime
8. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimum inhibitory concentration
9. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism minimum inhibitory concentration, and clinical condition on bacterial eradication
10. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
11. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
12. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve (AUIC) for cefmenoxime, ciprofloxacin, and tobramycin
13. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbation of chronic bronchitis
14. Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis
15. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia
16. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting
17. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex and weight
18. Some suggestions for measuring predictive performance
19. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
20. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae
21. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
22. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model
23. Population pharmacodynamic assessment of linezolid efficacy in community-acquired pneumonia, skin and soft tissue infections and bacteremia
24. Population pharmacodynamics of linezolid in seriously-ill adult patients from a compassionate-use protocol
25. Linezolid in the treatment of vancomycin resistant enterococcus: A dose comparative, multicenter Phase III trial